Literature DB >> 22130116

Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.

D E Gutstein1, R Krishna, D Johns, H K Surks, H M Dansky, S Shah, Y B Mitchel, J Arena, J A Wagner.   

Abstract

Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This review focuses on the highly selective and potent CE TP inhibitor anacetrapib and discusses the available preclinical and clinical information pertaining to it. We also describe strategies to target HDL-C, discuss the mechanism underlying CETP inhibition and its effects on lipid biology, and give an overview of other CETP inhibitors that are currently in development.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22130116     DOI： 10.1038/clpt.2011.271

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  15 in total

1.  Emerging roles for cholesterol and lipoproteins in lung disease.

Authors:  Kymberly M Gowdy; Michael B Fessler
Journal:  Pulm Pharmacol Ther       Date:  2012-06-15       Impact factor: 3.410

Review 2.  Pharmacotherapies for lipid modification: beyond the statins.

Authors:  Antonio M Gotto; Jennifer E Moon
Journal:  Nat Rev Cardiol       Date:  2013-08-20       Impact factor: 32.419

3.  Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Authors:  John S Millar; Gissette Reyes-Soffer; Patricia Jumes; Richard L Dunbar; Emil M deGoma; Amanda L Baer; Wahida Karmally; Daniel S Donovan; Hashmi Rafeek; Laura Pollan; Junichiro Tohyama; Amy O Johnson-Levonas; John A Wagner; Stephen Holleran; Joseph Obunike; Yang Liu; Rajasekhar Ramakrishnan; Michael E Lassman; David E Gutstein; Henry N Ginsberg; Daniel J Rader
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

4.  Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.

Authors:  Ronald M Krauss; Cathy Anne Pinto; Yang Liu; Amy O Johnson-Levonas; Hayes M Dansky
Journal:  J Clin Lipidol       Date:  2014-10-13       Impact factor: 4.766

Review 5.  LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?

Authors:  Joost Besseling; Julian van Capelleveen; John J P Kastelein; G Kees Hovingh
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

6.  CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.

Authors:  Bin Dong; Amar Bahadur Singh; Chin Fung; Kelvin Kan; Jingwen Liu
Journal:  Atherosclerosis       Date:  2014-06-04       Impact factor: 5.162

7.  Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.

Authors:  Michael Davidson; Sherry Xueyu Liu; Philip Barter; Eliot A Brinton; Christopher P Cannon; Antonio M Gotto; Elizabeth T Leary; Sukrut Shah; Michael Stepanavage; Yale Mitchel; Hayes M Dansky
Journal:  J Lipid Res       Date:  2012-11-19       Impact factor: 5.922

Review 8.  Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.

Authors:  Hisashi Shinkai
Journal:  Vasc Health Risk Manag       Date:  2012-05-15

Review 9.  Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels.

Authors:  Nathaniel Eraikhuemen; Dovena Lazaridis; Matthew T Dutton
Journal:  Am J Cardiovasc Drugs       Date:  2021-05       Impact factor: 3.571

Review 10.  The prevention and regression of atherosclerotic plaques: emerging treatments.

Authors:  Atul Ashok Kalanuria; Paul Nyquist; Geoffrey Ling
Journal:  Vasc Health Risk Manag       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.